Aetna modified CPB 0748 for panitumumab (Vectibix), effective January 5, 2026. Here's what billing teams need to know before submitting claims under J9303.
Aetna, a CVS Health company, updated its panitumumab (Vectibix) coverage policy under CPB 0748, tightening the criteria for colorectal cancer approvals and adding a second covered pathway for KRAS G12C-mutated disease. The primary billing codes affected are J9303 (injection, panitumumab, 10 mg) and the molecular testing codes 81275, 81276, and 81311 for RAS mutation analysis. If your oncology or infusion billing team hasn't reviewed this update, do it before submitting any new prior auth requests in 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Panitumumab (Vectibix) — CPB 0748 |
| Policy Code | CPB 0748 |
| Change Type | Modified |
| Effective Date | January 5, 2026 |
| Impact Level | High |
| Specialties Affected | Medical Oncology, Hematology/Oncology, Infusion Therapy, Gastroenterology |
| Key Action | Confirm RAS/BRAF mutation status and tumor sidedness documentation are in the precertification file before January 5, 2026 submissions |
Aetna Panitumumab Coverage Criteria and Medical Necessity Requirements 2026
The real issue with this update is how specific the medical necessity criteria have become. Aetna isn't just asking whether a patient has colorectal cancer. They're asking which mutation, which combination regimen, and — for colon cancer specifically — which side of the colon.
Aetna considers panitumumab (Vectibix) medically necessary for colorectal cancer, including appendiceal adenocarcinoma and anal adenocarcinoma. The disease must be unresectable, inoperable, advanced, or metastatic. The member also must not have previously experienced clinical failure on cetuximab (J9055).
Pathway 1: RAS Wild-Type Disease
This is the standard pathway most billing teams will recognize. All three of the following must be true:
| # | Covered Indication |
|---|---|
| 1 | RAS (KRAS and NRAS) mutation status is negative — wild-type |
| 2 | If the tumor carries a BRAF V600E mutation, panitumumab must be used in combination with encorafenib (Braftovi) |
| 3 | For first-line treatment of colon cancer (not rectal), the tumor must be left-sided only |
That last point is where denials will happen. The left-sided restriction applies to first-line colon cancer treatment. Rectal and rectosigmoid cancers (ICD-10 C19–C21.8) don't carry this restriction under the policy language. But colon cancer codes C18.0–C18.9 are listed as covered for left-sided tumors only. If your ICD-10 code is C18.3 (hepatic flexure — right side) and the clinical notes don't address tumor sidedness, expect a denial.
Pathway 2: KRAS G12C Mutation-Positive Disease
This is the newer pathway, and it's important. All three of the following must be true:
| # | Covered Indication |
|---|---|
| 1 | The disease is KRAS G12C mutation positive |
| 2 | Panitumumab is used in combination with sotorasib (Lumakras) or adagrasib (Krazati) |
| 3 | The member previously received chemotherapy |
This pathway matters because KRAS G12C was historically a dead end for anti-EGFR therapy. Pairing panitumumab with a KRAS inhibitor is a newer clinical strategy, and Aetna is now recognizing it in this coverage policy. The prior chemotherapy requirement is firm — document prior treatment lines in the precertification request.
Prior Authorization Requirements
Precertification is required for all Aetna participating providers and members in applicable plan designs. Call (866) 752-7021 or fax (888) 267-3277. SMN precertification forms are available through Aetna's Specialty Pharmacy Precertification portal.
Don't assume a prior authorization from last year carries forward. The effective date of January 5, 2026 means any new request — and any reauthorization — gets evaluated under the updated criteria.
Continuation of Therapy
Reauthorization is available when there's no evidence of unacceptable toxicity or disease progression on the current regimen. Document stable or responding disease at each reauthorization. Progression or unacceptable toxicity are the two clean denial triggers at reauth.
Aetna Panitumumab Exclusions and Non-Covered Indications
Aetna is explicit: all indications not listed in Section I of CPB 0748 are considered experimental, investigational, or unproven.
That's a broad exclusion. Panitumumab has investigational use in several tumor types — head and neck, non-small cell lung cancer, and others. The ICD-10 code list in this policy is long (238 codes), but coverage for those codes is not blanket approval. The policy criteria are colorectal cancer specific. Submitting J9303 with a lung cancer ICD-10 (C34.x) without meeting the CRC criteria will not get approved under this CPB.
Right-sided colon cancer in the first-line setting is also functionally excluded. The policy language limits first-line colon cancer coverage to left-sided tumors. If a member has right-sided colon cancer and RAS wild-type disease, panitumumab is not medically necessary under this policy in the first-line setting.
Coverage Indications at a Glance
| Indication | Status | Key Codes | Notes |
|---|---|---|---|
| CRC (unresectable/metastatic), RAS wild-type, left-sided colon (first-line) | Covered | J9303, C18.0–C18.9 | Left-sided restriction for colon only; prior auth required |
| CRC (unresectable/metastatic), RAS wild-type, rectal/rectosigmoid | Covered | J9303, C19–C21.8 | No sidedness restriction; prior auth required |
| CRC with BRAF V600E mutation, RAS wild-type | Covered (combination only) | J9303, 81210 | Must be combined with encorafenib; prior auth required |
| CRC, KRAS G12C mutation-positive | Covered (combination only) | J9303, 81275, 81276 | Must combine with sotorasib or adagrasib; prior chemo required |
| Appendiceal adenocarcinoma (if meeting criteria above) | Covered | J9303, C18.1 | Same mutation and regimen criteria apply |
| Anal adenocarcinoma (if meeting criteria above) | Covered | J9303, C21.0–C21.8 | Same mutation and regimen criteria apply |
| First-line right-sided colon cancer, RAS wild-type | Not Covered | C18.0–C18.9 | Excluded under first-line colon criteria |
| Any indication after cetuximab clinical failure | Not Covered | — | Explicit exclusion in policy |
| All other tumor types | Experimental/Unproven | — | No coverage under CPB 0748 |
Aetna Panitumumab Billing Guidelines and Action Items 2026
Panitumumab billing under the updated CPB 0748 is manageable — but only if your documentation workflow is locked down before claims go out. Here's what to do now.
| # | Action Item |
|---|---|
| 1 | Audit your active panitumumab patients against the new criteria before January 5, 2026. Pull every patient currently on panitumumab or pending a new start. Confirm RAS status, BRAF status if relevant, tumor sidedness for colon primaries, and prior treatment history for KRAS G12C patients. Missing any one of these at auth will cost you a denial. |
| 2 | Update your charge capture to link J9303 to molecular testing codes. Aetna will want mutation testing on file. CPT 81275 and 81276 cover KRAS variant analysis. CPT 81311 covers NRAS analysis. CPT 81210 covers BRAF V600E. If your billing team processes J9303 without verifying these testing codes were billed and documented, you're building a claim denial risk into every auth request. |
| 3 | Flag left-sided vs. right-sided colon cancer in your clinical documentation workflow. ICD-10 codes C18.0–C18.9 map to colon subsite, but they don't inherently specify laterality in the way the policy requires. The operative and pathology reports need to explicitly state tumor sidedness. Coordinate with your oncology documentation team to make this a standard field before the effective date. |
| 4 | Build the KRAS G12C combination pathway into your prior auth templates. If you're submitting for sotorasib + panitumumab or adagrasib + panitumumab combinations, the auth template needs to include: KRAS G12C confirmed positive, combination partner drug identified, and prior chemotherapy documented. Aetna's precertification line is (866) 752-7021 — train your auth team on the three-part checklist for this pathway. |
| 5 | Verify cetuximab history on every new panitumumab request. The policy excludes patients with prior clinical failure on cetuximab (J9055). If a patient was on cetuximab and came off due to progression, that's a disqualifying event under this policy. Document cetuximab history — or confirmed absence of it — in every prior auth submission. |
| 6 | Don't submit reimbursement claims for continuation therapy without current disease status documentation. Aetna's continuation criteria require no evidence of disease progression or unacceptable toxicity. At every reauthorization, get current imaging or clinical notes confirming stable or responding disease. A reauth without this is a soft denial waiting to happen. |
If your patient mix includes a high volume of CRC patients or you're in an infusion center billing across multiple mutation profiles, talk to your compliance officer before the effective date to review your internal auth workflows against these updated billing guidelines.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Panitumumab Under CPB 0748
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 81275 | CPT | KRAS gene analysis; variants in exon 2 |
| 81276 | CPT | KRAS gene analysis; additional variants (eg, codon 61, codon 146) |
| 81311 | CPT | NRAS gene analysis (eg, colorectal carcinoma) |
| 81404 | CPT | Molecular pathology procedure, Level 5 (eg, 2–5 exon analysis by DNA sequence) |
HCPCS Codes
| Code | Type | Description |
|---|---|---|
| J9303 | HCPCS | Injection, panitumumab, 10 mg — primary billing code |
| J9045 | HCPCS | Injection, carboplatin, 50 mg — related regimen agent |
| J9055 | HCPCS | Injection, cetuximab, 10 mg — relevant to cetuximab failure exclusion |
| J9190 | HCPCS | Injection, fluorouracil, 500 mg — related regimen agent |
| J9206 | HCPCS | Injection, irinotecan, 20 mg — related regimen agent |
| J9263 | HCPCS | Injection, oxaliplatin, 0.5 mg — related regimen agent |
Key ICD-10-CM Diagnosis Codes
| Code | Description | Coverage Note |
|---|---|---|
| C18.0 | Malignant neoplasm of cecum | Left-sided tumors only (first-line colon) |
| C18.1 | Malignant neoplasm of appendix | Left-sided tumors only |
| C18.2 | Malignant neoplasm of ascending colon | Left-sided tumors only |
| C18.3 | Malignant neoplasm of hepatic flexure | Left-sided tumors only |
| C18.4 | Malignant neoplasm of transverse colon | Left-sided tumors only |
| C18.5 | Malignant neoplasm of splenic flexure | Left-sided tumors only |
| C18.6 | Malignant neoplasm of descending colon | Left-sided tumors only |
| C18.7 | Malignant neoplasm of sigmoid colon | Left-sided tumors only |
| C18.8 | Malignant neoplasm of overlapping sites | Left-sided tumors only |
| C18.9 | Malignant neoplasm of colon, unspecified | Left-sided tumors only |
| C19 | Malignant neoplasm of rectosigmoid junction | Covered per criteria |
| C20 | Malignant neoplasm of rectum | Covered per criteria |
| C21.0–C21.8 | Malignant neoplasm of anus and anal canal | Covered per criteria |
Get the Full Picture for CPT 81275
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.